Skip to content

Liposomal versus hydrochloride bupivacaine for femoral nerve block on rebound pain after anterior cruciate ligament reconstruction: a randomized controlled trial

Liposomal versus hydrochloride bupivacaine for femoral nerve block on rebound pain after anterior cruciate ligament reconstruction: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124270
Enrollment
Unknown
Registered
2026-05-09
Start date
2026-05-10
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

Experimental group:All subjects received standardized postoperative multimodal analgesia. Additionally, an ultrasound-guided single-shot femoral nerve block (FNB) was performed. In the experimental gr
Control group:All subjects received standardized postoperative multimodal analgesia. Additionally, an ultrasound-guided single-shot femoral nerve block (FNB) was performed. In the control group, the b

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 65 years; 2.ASA physical status I-III; 3.BMI < 35 kg/m^2; 4.Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Clear history of IgE-mediated immediate hypersensitivity to amide local anesthetics (e.g., bupivacaine, ropivacaine, lidocaine, etc.); 2.Uncorrected coagulopathy, or current use of anticoagulant/antiplatelet drugs without reaching the safe discontinuation time recommended by corresponding guidelines; 3.Severe cardiac, pulmonary, hepatic, or renal dysfunction (e.g., NYHA class III-IV, severe organic damage such as myocardial infarction, oxygenation index 1.5 mg/dl, requirement for long-term dialysis, etc.); 4.Presence of peripheral neuropathy or chronic opioid use that may confound postoperative neurological assessment; 5.Pregnant or lactating women; 6.Active skin or soft tissue infection at the planned puncture site; 7.Inability to cooperate with pain scoring or follow-up.

Design outcomes

Primary

MeasureTime frame
Area under NRS score curve (AUC) at 12-72 hours after operation;

Secondary

MeasureTime frame
Total opioid consumption during 0–72 hours postoperatively, expressed as morphine milligram equivalents (MME);;Area under the curve (AUC) of movement-evoked pain Numeric Rating Scale (NRS) scores during 12–72 hours postoperatively;Time to first request for rescue analgesia;Patient satisfaction score (0–10);Incidence of adverse events;Quadriceps muscle strength (MMT grade 0–5);Length of hospital stay (days);Incidence of chronic pain at 30 days postoperatively, defined as NRS = 3.;

Countries

China

Contacts

Public ContactWang Qingxiang

The First Affiliated Hospital of Xiamen University

qxw82@163.com+86 158 8024 1005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026